Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

[1]  J. Brieger,et al.  Transcriptional regulation of the VEGF gene in dependence of individual genomic variations. , 2015, Cytokine.

[2]  S. Steinberg,et al.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. , 2015, JAMA oncology.

[3]  R. Motzer,et al.  Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. , 2015, Clinical genitourinary cancer.

[4]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[5]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[6]  G. Lourenço,et al.  Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma , 2014, Annals of Hematology.

[7]  U. Vogel,et al.  Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma , 2012, International journal of cancer.

[8]  A. Liberati,et al.  Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma , 2012, Advances in hematology.

[9]  D. Ribatti,et al.  Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma , 2011, Clinical Cancer Research.

[10]  G. Giaccone,et al.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib , 2010, Journal of experimental & clinical cancer research : CR.

[11]  I. Brandslund,et al.  The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. , 2010, Gynecologic oncology.

[12]  D. Venzon,et al.  The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors , 2009, Molecular Cancer Therapeutics.

[13]  Yibo Wang,et al.  Polymorphisms of KDRGene Are Associated With Coronary Heart Disease , 2007 .

[14]  Yibo Wang,et al.  Polymorphisms of KDR gene are associated with coronary heart disease. , 2007, Journal of the American College of Cardiology.

[15]  F. B. Sørensen,et al.  Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival , 2005, British journal of haematology.

[16]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[17]  R. Fonseca,et al.  Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.